A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

​ Conditions: Venous Malformations; Lymphatic Malformations; Klippel-Trenaunay Syndrome; CLOVES Syndrome

Interventions: Drug: KP-001; Drug: Placebo

Sponsors: Kaken Pharmaceutical

Not yet recruiting Conditions: Venous Malformations; Lymphatic Malformations; Klippel-Trenaunay Syndrome; CLOVES Syndrome
Interventions: Drug: KP-001; Drug: Placebo
Sponsors: Kaken Pharmaceutical
Not yet recruiting